Digestive Enzyme 6-30-19 Capsule
Natural health product licensed in Canada
- Licence holder
- BIOVANTEK
- NPN or DIN-HM
- 80069912
- Status
- Inactive licence
- Licence date
- 3 June 2016
- Revision date
- 18 May 2022
- Form
- Capsule, libération-retardée
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Enzymes pancréatiques Source : Sus scrofa - pancréas Potency : 19,000 Unités de la Pharmacopée des États-Unis Protease | 375 milligramme | Not calculated |
| Enzymes pancréatiques Source : Sus scrofa - pancréas Potency : 30,000 Unités de la Pharmacopée des États-Unis alpha-Amylase | Not specified | Not calculated |
| Enzymes pancréatiques Source : Sus scrofa - pancréas Potency : 6,000 Unités de la Pharmacopée des États-Unis Triacylglycerol lipase | Not specified | Not calculated |
Non-medicinal ingredients
Maltodextrine, Stéarate de magnésium, Gélatine, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Digestive aid. Digestive enzyme.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
If you are sensitive to pancreatic enzymes, do not use this product. If you are sensitive to pork proteins, do not use this product.
- Effets indésirables connus
Nausea, vomiting, abdominal pain/epigastric pain and/or heartburn have been known to occur, in which case discontinue use (and consult a health care practitioner).
- Précautions et mises en garde
If symptoms persist or worsen, consult a health care practitioner. If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If you have diabetes, consult a health care practitioner prior to use. If you have pancreatitis, pancreatic exocrine insufficiency or cystic fibrosis, consult a health care practitioner prior to use.
Source
Official Health Canada record, licence 80069912
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging